23,900 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 23,900 shares of the specialty pharmaceutical company's stock, valued at approximately $2,536,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allianz Asset Management GmbH grew its stake in Jazz Pharmaceuticals by 453.9% during the 2nd quarter. Allianz Asset Management GmbH now owns 325,403 shares of the specialty pharmaceutical company's stock worth $34,532,000 after buying an additional 266,658 shares during the last quarter. New York State Teachers Retirement System grew its stake in Jazz Pharmaceuticals by 0.5% during the 2nd quarter. New York State Teachers Retirement System now owns 44,077 shares of the specialty pharmaceutical company's stock worth $4,677,000 after buying an additional 230 shares during the last quarter. Ritholtz Wealth Management grew its stake in Jazz Pharmaceuticals by 8.1% during the 2nd quarter. Ritholtz Wealth Management now owns 16,533 shares of the specialty pharmaceutical company's stock worth $1,754,000 after buying an additional 1,237 shares during the last quarter. Bayforest Capital Ltd grew its stake in Jazz Pharmaceuticals by 222.6% during the 2nd quarter. Bayforest Capital Ltd now owns 5,791 shares of the specialty pharmaceutical company's stock worth $615,000 after buying an additional 3,996 shares during the last quarter. Finally, Boston Trust Walden Corp grew its stake in Jazz Pharmaceuticals by 129.1% during the 2nd quarter. Boston Trust Walden Corp now owns 407,897 shares of the specialty pharmaceutical company's stock worth $43,286,000 after buying an additional 229,885 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Needham & Company LLC restated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Finally, Truist Financial boosted their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $179.80.

Insider Activity

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Up 2.0%

Jazz Pharmaceuticals stock opened at $137.50 on Wednesday. The company has a market cap of $8.34 billion, a PE ratio of -20.43, a PEG ratio of 8.28 and a beta of 0.28. The business's 50-day simple moving average is $129.17 and its two-hundred day simple moving average is $116.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.